Fate Therapeutics Inc (NASDAQ:FATE) CEO J Scott Wolchko sold 8,541 shares of Fate Therapeutics stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $16.17, for a total transaction of $138,107.97. Following the completion of the transaction, the chief executive officer now owns 375,973 shares in the company, valued at approximately $6,079,483.41. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
J Scott Wolchko also recently made the following trade(s):
- On Thursday, March 21st, J Scott Wolchko sold 20,000 shares of Fate Therapeutics stock. The stock was sold at an average price of $17.61, for a total transaction of $352,200.00.
Shares of Fate Therapeutics stock opened at $16.02 on Friday. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -13.46 and a beta of 2.05. Fate Therapeutics Inc has a 12-month low of $8.35 and a 12-month high of $19.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.53 and a current ratio of 7.53.
Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Fate Therapeutics had a negative return on equity of 59.04% and a negative net margin of 1,405.06%. Research analysts expect that Fate Therapeutics Inc will post -1.05 earnings per share for the current fiscal year.
FATE has been the topic of a number of analyst reports. BidaskClub cut shares of Fate Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 19th. Zacks Investment Research cut shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 7th. Stephens cut shares of Fate Therapeutics from an “overweight” rating to an “equal” rating in a research report on Thursday, January 3rd. Wedbush lifted their target price on shares of Fate Therapeutics from $19.00 to $21.00 and gave the stock an “outperform” rating in a research report on Monday, February 11th. Finally, Wells Fargo & Co lifted their target price on shares of Fate Therapeutics from $18.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.63.
A number of institutional investors have recently made changes to their positions in FATE. BlackRock Inc. grew its holdings in Fate Therapeutics by 45.0% in the 4th quarter. BlackRock Inc. now owns 5,031,783 shares of the biopharmaceutical company’s stock worth $64,557,000 after acquiring an additional 1,562,252 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Fate Therapeutics by 150.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,318,860 shares of the biopharmaceutical company’s stock worth $16,921,000 after acquiring an additional 791,540 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Fate Therapeutics by 269.0% during the 4th quarter. Millennium Management LLC now owns 587,640 shares of the biopharmaceutical company’s stock valued at $7,539,000 after purchasing an additional 428,399 shares in the last quarter. Aquilo Capital Management LLC boosted its stake in shares of Fate Therapeutics by 69.7% during the 3rd quarter. Aquilo Capital Management LLC now owns 984,596 shares of the biopharmaceutical company’s stock valued at $16,039,000 after purchasing an additional 404,367 shares in the last quarter. Finally, Vanguard Group Inc boosted its stake in shares of Fate Therapeutics by 12.7% during the 3rd quarter. Vanguard Group Inc now owns 2,448,279 shares of the biopharmaceutical company’s stock valued at $39,882,000 after purchasing an additional 275,828 shares in the last quarter. 91.71% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Fate Therapeutics Inc (FATE) CEO J Scott Wolchko Sells 8,541 Shares” was originally published by Highlight Press and is the property of of Highlight Press. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://highlightpress.com/2019/04/20/fate-therapeutics-inc-fate-ceo-j-scott-wolchko-sells-8541-shares.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.